Stock SXTP 60 DEGREES PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

60 Degrees Pharmaceuticals, Inc. Stock

Equities

SXTP

US83006G1040

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-16 pm EDT 		5-day change 1st Jan Change
0.234 USD +1.92% Intraday chart for 60 Degrees Pharmaceuticals, Inc. -3.94% -77.06%
Jul. 09 60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia Microti Despite Prior Treatment CI
Jun. 27 60 Degrees Pharmaceuticals, Inc. Announces First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center CI

Financials (USD)

Sales 2024 * 912K Sales 2025 * 2.57M Capitalization 2.8M
Net income 2024 * -5M Net income 2025 * -4M EV / Sales 2024 * 3.07 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.09 x
P/E ratio 2024 *
-0.49 x
P/E ratio 2025 *
-1.02 x
Employees 3
Yield 2024 *
-
Yield 2025 *
-
Free-Float 76.33%
More Fundamentals * Assessed data

Chart 60 Degrees Pharmaceuticals, Inc.

Dynamic Chart

Latest news about 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia Microti Despite Prior Treatment CI
60 Degrees Pharmaceuticals, Inc. Announces First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center CI
60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients CI
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study CI
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required CI
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024 CI
60 Degrees Pharmaceuticals, Inc. Appoints Kristen Landon as Chief Commercial Officer CI
60 Degrees Pharmaceuticals Closes $2.4 Million Public Offering MT
Top Midday Decliners MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
60 Degrees Pharmaceuticals Planning Study of Tick-Borne Disease With Malaria Drug; Shares Jump MT
60 Degrees Pharma Shares Rise 18% After Type C Meeting With FDA DJ
60 Degrees Pharma Plans Tafenoquine Study After FDA Meeting DJ
More news

Analyst Recommendations on 60 Degrees Pharmaceuticals, Inc.

Ascendiant Capital Starts 60 Degrees Pharmaceuticals at Buy With $2.40 Price Target MT
More recommendations

Press releases 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment AQ
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind AQ
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis AQ
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind AQ
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study AQ
More press releases

Quotes and Performance

1 day+1.92%
1 week-3.94%
Current month-7.47%
1 month-14.32%
3 months-10.00%
6 months-76.49%
Current year-77.06%
More quotes

Highs and lows

1 week
0.22
Extreme 0.2205
0.27
1 month
0.22
Extreme 0.215
0.29
Current year
0.20
Extreme 0.2011
1.13
1 year
0.20
Extreme 0.2011
3.53
3 years
0.20
Extreme 0.2011
8.65
5 years
0.20
Extreme 0.2011
8.65
10 years
0.20
Extreme 0.2011
8.65
More quotes

Quotes

Date Price Change Volume
24-07-16 0.234 +1.92% 151,135
24-07-15 0.2296 -6.48% 162,674
24-07-12 0.2455 -0.20% 278,937
24-07-11 0.246 +8.32% 1,516,522
24-07-10 0.2271 -6.77% 1,196,026

Delayed Quote Nasdaq, July 16, 2024 at 04:00 pm EDT

More quotes

Company Profile

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Sector
Pharmaceuticals
More about the company

Income Statement Evolution

More financial data

Ratings for 60 Degrees Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.234 USD
Average target price
1.3 USD
Spread / Average Target
+455.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
60 DEGREES PHARMACEUTICALS, INC. Stock 60 Degrees Pharmaceuticals, Inc.
-77.06% 2.8M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+61.53% 856B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.95% 631B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.66% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.06% 325B
ABBVIE INC. Stock AbbVie Inc.
+9.18% 297B
ROCHE HOLDING AG Stock Roche Holding AG
+5.89% 234B
NOVARTIS AG Stock Novartis AG
+16.53% 226B
AMGEN INC. Stock Amgen Inc.
+15.67% 177B
PFIZER, INC. Stock Pfizer, Inc.
+2.47% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SXTP Stock